No morbidity-mortality. Commentary.
Malik
R A
RA
Department of Medicine, Manchester Royal Infirmary, Manchester, UK.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000804:Angiotensin II; D057911:Angiotensin Receptor Antagonists; D001262:Atenolol / Q000627:therapeutic use; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000401:mortality; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000401:mortality; D019808:Losartan / Q000627:therapeutic use*; D008875:Middle Aged; D009017:Morbidity; D018579:Patient Selection
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000804:Angiotensin II; D001262:Atenolol; D019808:Losartan